Immunotherapy plus chemotherapy for stomach cancer spread to the belly
Part of Cancer, Digestive system clinical trials.
This study tests a combination of two treatments for stomach cancer that has spread to the lining of the belly. It uses an immunotherapy drug (tislelizumab) plus standard chemotherapy (SOX) and a heated chemotherapy treatment directly into the belly (HIPEC) to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of stomach cancer called gastric adenocarcinoma that is HER2-negative (a specific protein marker).
- You are between 18 and 80 years old and in fairly good physical condition (able to do light activities).
- The cancer has spread only to the lining of your belly (peritoneum) or caused fluid buildup (ascites), but not to other organs like the liver or lungs.
- Your cancer has not caused a blockage, hole, or high risk of bleeding in the stomach or intestines.
- Your blood counts (white cells, platelets, hemoglobin) and liver/kidney function tests are within acceptable limits.
- You have not had chemotherapy, radiation, or other cancer treatments before, and you are willing to provide blood and tissue samples.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a treatment approach for stomach cancer that hasn't spread to other organs. It's for people who have not had any prior cancer treatments and are in relatively good health.
This trial tests combining standard chemotherapy and immunotherapy (tirelizumab) with heated chemotherapy given directly into the belly. It aims to treat stomach cancer that has spread to the abdominal lining, and may help shrink or control the cancer.
This study tests a combination of an immunotherapy drug (tislelizumab) with two chemotherapy drugs (called the SOX regimen) given before surgery for locally advanced stomach cancer. The goal is to see if this treatment can shrink the tumor and make it easier to remove completely during surgery.
This trial tests a combination of treatments for stomach cancer that has spread to the lining of the abdomen. The goal is to see if this approach can shrink or control the cancer, potentially making surgery possible.
This trial tests whether adding an immunotherapy drug (tislelizumab) to standard chemotherapy after surgical removal of stomach cancer can prevent the cancer from returning in older adults (aged 65 and above). The study aims to see if this combination improves outcomes compared to chemotherapy alone.
This trial combines heated chemotherapy directly into the abdomen (HIPEC) with standard chemotherapy and an immunotherapy drug to treat advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Gastric Cancer with Peritoneal Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.